Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry

Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry

Daclizumab beta is a humanized monoclonal antibody that binds to CD25 and selectively inhibits high-affinity IL-2 receptor signaling. As a former treatment for relapsing forms of multiple sclerosis (RMS), daclizumab beta induces robust expansion of the CD56bright subpopulation of NK cells that is co...

Full description

Bibliographic Details
Main Authors: Thanmayi Ranganath, Laura J. Simpson, Anne-Maud Ferreira, Christof Seiler, Elena Vendrame, Nancy Zhao, Jason D. Fontenot, Susan Holmes, Catherine A. Blish
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Immunology
Subjects:
natural killer cell
daclizumab beta
multiple sclerosis
immune profiling
CyTOF/mass cytometry
uniform manifold approximation and projection
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00714/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00714/full

Similar Items